New hope for rare blood cancers: targeted drug trial opens
NCT ID NCT06716658
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have not responded to standard therapy. The goal is to see if the drug can shrink or control the cancer. About 48 adults will take the drug by mouth, and researchers will track how many respond and what side effects occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA (CTCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
NOT_YET_RECRUITINGTianjin, 300020, China
-
Institute of Hematology & Blood Diseases Hospital, China
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart a rare skin cancer?
- A microchip implanted in tumors could reveal which drugs work best
- Engineered immune cells take aim at hard-to-treat blood cancers
- Skin gel targets immune signals in rare lymphoma
- Could an ALS drug clear the fog of chemo brain?
- Combination therapy aims to boost response in rare skin cancers